Palatin Technologies, Inc.
A biopharmaceutical company that develops medicines working on the body's melanocortin receptor system, Palatin Technologies is headquartered in Princeton, New Jersey. Its most visible product is Vyleesi, an FDA-approved injectable treatment for low sexual desire in premenopausal women, delivered through a self-administered autoinjector. Founded in 1986 by Carl Spana and John K.A. Prendergast, the company also develops treatments for obesity and rare metabolic disorders.
Granted 12.0K · Bought 106.0K · Sold 11.7K
Granted 113.1K · Bought 1.5K
Granted 98.8K · Bought 1.5K · Sold 10.6K
Granted 12.0K
Granted 12.0K
Granted 12.0K
Granted 14.0K · Bought 200 · Sold 200
Granted 18.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Deveer Robert K JrDirector · 10 transactions | +181.3% | 138.1Kas of May 2025 | 12.0K | 106.0K | 11.7K |
| Spana CarlPresident and CEO, Director · 24 transactions | -82.9% | 64.4K | 113.1K | 1.5K | — |
| Wills Stephen TExecutive VP and CFO/COO · 29 transactions | -81.1% | 63.4K | 98.8K | 1.5K | 10.6K |
| Hull Joseph StanleyDirector · 1 transaction | -11.2% | 42.3Kas of Jul 2024 | 12.0K | — | — |
| Morris ArleneDirector · 1 transaction | -7.8% | 41.6Kas of Jul 2024 | 12.0K | — | — |
| Manning Anthony M.Director · 1 transaction | -1.7% | 36.1Kas of Jul 2024 | 12.0K | — | — |
| Dunton Alan WDirector · 6 transactions | -70.5% | 14.1K | 14.0K | 200 | 200 |
| Prendergast John K ADirector · 3 transactions | -82% | 13.8K | 18.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +86.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.